Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref.
studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

GLUCOCOVID, 2020 RCTcorticosteroidscontrolCOVID 19 hospitalizedhigh
34/29 suggested
  • suggested 45 % decrease in clinical deterioration but with a low degree of certainty due to high risk of bias
Metcovid, 2020
  NCT04343729		 RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
209/207 inconclusive
  • inconclusive 8 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
RECOVERY dexamethasone, 2020
  NCT04381936		 RCTdexamethasonestandard of careCOVID 19 hospitalizedsome concern
2104/4321 conclusif
  • demonstrated 17 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 10 % increase in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
in an exploratory subgroup analysis there was no benefit among patients who did not require oxygen (1.22 [0.86 to 1.75]; p=0.14)
Fernández Cruz, 2020 OBScorticosteroidsstandard of careCOVID 19 hospitalizedserious
396/67 suggested
  • suggested 66 % decrease in deaths but with a low degree of certainty due to high risk of bias

COVID-19 severe or critically meta-analysis

CAPE-COVID, 2020
  NCT02517489		 RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
76/73 inconclusive
  • inconclusive 29 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
COALITION II (Furtado), 2020
  NCT04321278		 RCTHydrocortisonehydroxychloroquineCOVID-19 severe or criticallysome concern
214/183 inconclusive
    CODEX (Tomazini), 2020
          NCT04327401    		 RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
    		151/148 inconclusive
      Edalatifard, 2020
              IRCT20200404046947N1      		 RCTmethylprednisolonestandard of careCOVID-19 severe or criticallyhigh
      		34/34 conclusif
      • demonstrated 71 % decrease in deaths (PE) but with a low degree of certainty due to high risk of bias
      REMAP-CAP, fixed 7-day course, 2020
              NCT02735707      		 RCTHydrocortisonestandard of careCOVID-19 severe or criticallysome concern
      		143/108 inconclusive
        REMAP-CAP, shock-dependent course, 2020
                  NCT02735707        		 RCTcorticosteroidsstandard of careCOVID-19 severe or criticallysome concern
        		152/108 inconclusive
          Jianfeng, 2020 OBScorticosteroidsstandard of careCOVID-19 severe or criticallyserious
          		-/- safety concern
          • statistically significant 1.8-fold increase in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
          • statistically significant 2.0-fold increase in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
          Raef, 2020 OBScorticosteroidsstandard of careCOVID-19 severe or criticallycritical
          		-/- suggested
          • suggested 55 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
          Lu, 2020 OBScorticosteroidscontrolCOVID-19 severe or criticallyserious
          		151/93 inconclusive

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

             

            - About us - Contact us - Method Made with in Lyon - Credits - Privacy policy - Licence Creative Commons